Focal Therapy (FT) is an emerging treatment modality for prostate cancer (PCa). Due to its novelty, the research exploring how patients should be followed-up after treatment is limited. There is currently no established role for non-prostate-specific-antigen (PSA) biomarkers and PSMA PET. However, a combination of PSA testing, multiparametric magnetic resonance imaging (mpMRI), and systematic and targeted biopsies should routinely be used for surveillance after FT. PSA values that rise 1.0 ng/mL over the nadir after twelve months or rise 1.5 ng/mL over nadir after twenty-four to thirty-six months should raise suspicion for recurrence. The standard imaging technique is mpMRI, but it can often be difficult to interpret after FT, so using a scoring system such as prostate imaging after focal ablation (PI-FAB) or the transatlantic recommendations for prostate gland evaluation with magnetic resonance imaging after focal therapy (TARGET) allows for greater consistency between readers. This review seeks to summarize the current literature regarding surveillance after FT as it relates to biomarkers, imaging, biopsies, and consensus statements.
局部治疗（FT）是前列腺癌（PCa）的一种新兴治疗方式。由于其新颖性，关于治疗后患者应如何随访的研究较为有限。目前，非前列腺特异性抗原（PSA）生物标志物和PSMA PET尚未确立明确作用。然而，在FT后的监测中，应常规联合使用PSA检测、多参数磁共振成像（mpMRI）以及系统性和靶向活检。若PSA值在治疗后十二个月内较最低值上升1.0 ng/mL，或在二十四至三十六个月内上升1.5 ng/mL，应警惕复发可能。标准影像学技术为mpMRI，但FT后其结果常难以解读，因此采用如局部消融后前列腺成像（PI-FAB）评分系统或跨大西洋局部治疗后前列腺磁共振成像评估共识（TARGET）等标准化评估体系，可提高不同阅片者之间的一致性。本综述旨在总结当前关于FT后监测的文献，涵盖生物标志物、影像学、活检及共识声明等方面。
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review
肿瘤(癌症)患者之家